Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-11

Yep
should the interim analysis on the 42X phase 2/3 trial back up the phase 2 proof of concept AND safety and efficacy beat the 49/51 FDA risk benefit approval analysis rating - based on that data 42X will smash the OSA unmet need marketwide open
Big Pharma will have the inside running if they offer the right coin for that asset alone and those interim results will drive that value based on development and generated horizon revenues

'so many pipelines' - lol....worth billions